Promising Penny Stocks To Consider In May 2026

Simply Wall St.05-15 19:05

The United States market has shown impressive growth, with a 1.1% increase over the last week and a substantial 27% rise over the past year, alongside expectations for earnings to grow by 17% annually...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2635896510?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-05-15 19:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2635896510","market":"nz","top_or_hot":-1,"title":"Promising Penny Stocks To Consider In May 2026","media":"Simply Wall St.","content":"<div>\n<p>The United States market has shown impressive growth, with a 1.1% increase over the last week and a substantial 27% rise over the past year, alongside expectations for earnings to grow by 17% annually...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ltrn/lantern-pharma/news/promising-penny-stocks-to-consider-in-may-2026\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Promising Penny Stocks To Consider In May 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPromising Penny Stocks To Consider In May 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-15 19:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ltrn/lantern-pharma/news/promising-penny-stocks-to-consider-in-may-2026><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The United States market has shown impressive growth, with a 1.1% increase over the last week and a substantial 27% rise over the past year, alongside expectations for earnings to grow by 17% annually...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ltrn/lantern-pharma/news/promising-penny-stocks-to-consider-in-may-2026\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LTRN","symbol_name":"Lantern Pharma Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ltrn/lantern-pharma/news/promising-penny-stocks-to-consider-in-may-2026","article_id":"2635896510","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ltrn/lantern-pharma/news/promising-penny-stocks-to-consider-in-may-2026","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2635896510","pubTimestamp":1778843111,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"The United States market has shown impressive growth, with a 1.1% increase over the last week and a substantial 27% rise over the past year, alongside expectations for earnings to grow by 17% annually in the coming years. Penny stocks, while an older term, continue to capture attention as they often represent smaller or newer companies that provide growth opportunities at lower price points. By focusing on those with strong financial health and solid fundamentals, investors can uncover...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LTRN":"Lantern Pharma Inc.","ZJK":"中金科五金","BK4134":"信息科技咨询与其它服务","LU0049112450.USD":"FIDELITY PACIFIC \"A\" INC","BK4509":"腾讯概念","NAGE":"Niagen Bioscience","BK4023":"应用软件","TUYA":"涂鸦智能","LX":"乐信","BK4121":"生命科学工具和服务","BK4161":"工业机械","LU1235295612.USD":"FIDELITY PACIFIC \"A\" (USDHDG) INC","BK4531":"中概回港概念","BABB":"BAB, Inc.","III":"信息服务","BK4526":"热门中概股","BK4189":"农产品","BK4139":"生物科技","HLP":"宏力型钢","BK4006":"钢铁","LU1046422090.SGD":"Fidelity Pacific A-SGD","FINV":"信也科技","BK4505":"高瓴资本持仓","VFF":"Village Farms International Inc","BK4166":"消费信贷","SPRO":"Spero Therapeutics Inc.","BK4209":"餐馆","BK4579":"人工智能","BK4183":"个人用品"},"translate_title":"2026年5月值得考虑的有前途的细价股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HLP":1,"FINV":1,"TUYA":1,"VFF":1,"LX":1,"III":1,"LTRN":1,"BABB":1,"NAGE":1,"ZJK":1,"SPRO":1},"content_text":"The United States market has shown impressive growth, with a 1.1% increase over the last week and a substantial 27% rise over the past year, alongside expectations for earnings to grow by 17% annually in the coming years. Penny stocks, while an older term, continue to capture attention as they often represent smaller or newer companies that provide growth opportunities at lower price points. By focusing on those with strong financial health and solid fundamentals, investors can uncover potential gems within this niche area of the market.AdvertisementTop 10 Penny Stocks In The United StatesNameShare PriceMarket CapRewards & RisksZJK Industrial (ZJK)$2.88$180.1M✅ 3 ⚠️ 2 View Analysis >LexinFintech Holdings (LX)$2.02$341.11M✅ 3 ⚠️ 2 View Analysis >Tuya (TUYA)$2.17$1.38B✅ 4 ⚠️ 1 View Analysis >FinVolution Group (FINV)$4.94$1.25B✅ 4 ⚠️ 1 View Analysis >Information Services Group (III)$3.11$203.8M✅ 3 ⚠️ 0 View Analysis >Golden Growers Cooperative (GGRO.U)$5.00$77.45M✅ 2 ⚠️ 5 View Analysis >Niagen Bioscience (NAGE)$3.80$300.09M✅ 3 ⚠️ 1 View Analysis >Village Farms International (VFF)$2.64$297.15M✅ 5 ⚠️ 1 View Analysis >BAB (BABB)$0.9416$6.91M✅ 2 ⚠️ 3 View Analysis >Marine Petroleum Trust (MARP.S)$4.975$10M✅ 2 ⚠️ 3 View Analysis >Click here to see the full list of 358 stocks from our  US Penny Stocks screener.Let's uncover some gems from our specialized screener.Hongli Group (HLP)Simply Wall St Financial Health Rating: ★★★★★☆Overview: Hongli Group Inc., along with its subsidiaries, manufactures and sells customized metal profiles in China and internationally, with a market cap of $86.70 million.Operations: No revenue segments have been reported.Market Cap: $86.7MHongli Group Inc. has recently reported a significant turnaround with annual sales reaching US$19.6 million and net income of US$1.94 million, marking profitability compared to the previous year's loss. Despite this positive development, the company faces challenges such as volatile share prices and delayed SEC filings, which may concern investors about transparency and stability. The company's debt management shows improvement with a satisfactory net debt to equity ratio of 16.8%, although operating cash flow coverage remains weak at 7.6%. A recent private placement raised US$325,000, potentially supporting future operations or strategic initiatives.Get an in-depth perspective on Hongli Group's performance by reading our balance sheet health report here.Assess Hongli Group's previous results with our detailed historical performance reports.HLP Financial Position Analysis as at May 2026Lantern Pharma (LTRN)Simply Wall St Financial Health Rating: ★★★★★★Overview: Lantern Pharma Inc. is engaged in the discovery and development of oncology drugs in India, with a market cap of $28.13 million.Operations: Lantern Pharma does not report any revenue segments.Market Cap: $28.13MLantern Pharma Inc., with a market cap of US$28.13 million, is pre-revenue and focused on oncology drug development using AI-driven platforms. The recent US$4.4 million equity offering aims to bolster its cash runway beyond the current eight months. Despite no debt and experienced management, Lantern's financials show increased losses over five years and forecasted earnings decline by 9.6% annually for three years. The launch of the withZeta.ai platform introduces potential non-dilutive revenue streams through subscriptions, yet profitability remains elusive as it navigates a volatile share price environment and auditor concerns about its going concern status persist.Click to explore a detailed breakdown of our findings in Lantern Pharma's financial health report.Gain insights into Lantern Pharma's future direction by reviewing our growth report.LTRN Financial Position Analysis as at May 2026Spero Therapeutics (SPRO)Simply Wall St Financial Health Rating: ★★★★★★Overview: Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for multi-drug resistant bacterial infections and rare diseases in the United States, with a market cap of $141.28 million.Operations: Spero Therapeutics, Inc. does not report any specific revenue segments.Market Cap: $141.28MSpero Therapeutics, Inc., with a market cap of US$141.28 million, has transitioned to profitability and reported significant revenue growth last year but experienced a decline in the recent quarter. Despite this volatility, its strong balance sheet shows short-term assets exceeding liabilities and no debt burden. The company’s high return on equity of 28.8% reflects efficient capital use, while its seasoned management and board bolster strategic direction. Recent amendments to increase authorized shares signal potential future capital raising activities as it navigates the competitive biotech landscape with innovative treatments for resistant infections and rare diseases.Navigate through the intricacies of Spero Therapeutics with our comprehensive balance sheet health report here.Gain insights into Spero Therapeutics' past trends and performance with our report on the company's historical track record.SPRO Revenue & Expenses Breakdown as at May 2026Where To Now?Click through to start exploring the rest of the 355   US Penny Stocks now.Interested In Other Possibilities? These 22 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.  This article by Simply Wall St is general in nature. We provide commentary based on historical data \n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your \n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data. \n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. \n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2635896510","isCrawlerRequest":true}